wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q27853127-189613F5-D3ED-4173-A48C-DCA584BF4D33
Q27853127-189613F5-D3ED-4173-A48C-DCA584BF4D33
BestRank
Statement
http://www.wikidata.org/entity/statement/Q27853127-189613F5-D3ED-4173-A48C-DCA584BF4D33
A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer
P2860
Q27853127-189613F5-D3ED-4173-A48C-DCA584BF4D33
BestRank
Statement
http://www.wikidata.org/entity/statement/Q27853127-189613F5-D3ED-4173-A48C-DCA584BF4D33
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
61053855b8a868c17c08362998faad71ce06c8df
P2860
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer.